Frontiers | PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
PD-L1 on dendritic cells controls the antitumor response
PD-L1 is a negative prognostic marker for patients with mesothelioma.... | Download Scientific Diagram
Tumor-associated PD-L1-positive immune cells stain positive for... | Download Scientific Diagram
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma | Virchows Archiv
Immun-Checkpoint Marker - Antikörper für die Immunhistochemie | BIOZOL
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy: Trends in Cancer
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer: Molecular Therapy
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy: Trends in Cancer
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors | Scientific Reports
Cancers | Free Full-Text | Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
PD-L1 expression on tumor cells (TC) and tumor infiltrating immune... | Download Scientific Diagram
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors | Molecular Cancer | Full Text
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
IJMS | Free Full-Text | PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer | Oncotarget
A snapshot of the PD-1/PD-L1 pathway
PD-L1 as a biomarker of response to immune-checkpoint inhibitors | Nature Reviews Clinical Oncology
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy | Science Translational Medicine
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Präzisionsmedizin - PD-L1 | Ihr Fachportal für Onkologie und Hämatologie | BMS-Onkologie
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
JCI - Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
Full article: Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer - eBioMedicine
